Navigation Links
Alexza Pharmaceuticals to Present at Bank of America Merrill Lynch 2010 Specialty Pharmaceuticals Conference
Date:8/6/2010

MOUNTAIN VIEW, Calif., Aug. 6 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that company Senior Vice President and Chief Financial Officer, August J. Moretti will present during the Bank of America Merrill Lynch 2010 Specialty Pharmaceuticals Conference.  The Alexza presentation will be on Friday, August 13, 2010 at 10:40 am ET.  The presentation will be webcast from the Southampton Inn in Southampton, New York.

To access the presentation via the Web, please go to the Investor Relations tab at www.alexza.com or at https://www.veracast.com/webcasts/bas/specpharma2010/id10116040.cfm.  A replay of the webcast will be made available approximately 24 hours after the live presentation and the replay will be archived for 14 days.

About Alexza Pharmaceuticals, Inc.

Alexza Pharmaceuticals is a pharmaceutical company focused on the research, development and commercialization of novel, proprietary products for the acute treatment of central nervous system conditions.  Alexza's technology, the Staccato®
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Alexza Pharmaceuticals Appoints Joseph L. Turner to Its Board of Directors
2. Alexza to Announce 2010 Second Quarter Financial Results on Monday, July 26, 2010
3. Alexza Pharmaceuticals Updates Staccato® Pipeline and Outlines Pipeline Development Strategy
4. Alexza Pharmaceuticals to Present at Jefferies 2010 Global Life Sciences Conference
5. Alexza Secures $25 Million Committed Equity Financing Facility With Azimuth Opportunity, Ltd.
6. Alexza Pharmaceuticals to Present at The Ninth Annual JMP Securities Research Conference
7. Alexza Executes $15 million Working Capital Loan with Hercules Technology Growth Capital, Inc.
8. Alexza Pharmaceuticals Files Shelf Registration Statement
9. Alexza to Announce 2010 First Quarter Financial Results on Monday, May 10, 2010
10. Alexza Reports 2009 Fourth Quarter and Full Year Financial Results and Provides General Corporate Update
11. Alexza Pharmaceuticals Promotes Mark K. Oki to Vice President, Finance and Controller
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... 2015 Research and Markets ... of the "Lab Accessories Market by ... Station) & End User (OEM/Biotechnology & Pharmaceutical ... 2020" report to their offering. ... expected to reach $504.7 million by 2020 ...
(Date:4/24/2015)... Company, Inc. (NYSE: LCI ) today announced that ... facility to $120 million from $50 million.  The amended ... company to increase borrowings by a total of up ... commitments from existing lenders or new lending institutions.  The ... 2018.   "The amended credit facility, together ...
(Date:4/23/2015)... CHICAGO, Ill. , April 24, 2015  AbbVie ... Food and Drug Administration (FDA) has accepted its New ... company,s, all-oral, interferon-free, two direct-acting antiviral treatment of ombitasvir, ... for the treatment of adults with chronic genotype 4 ... regimen is the first all-oral, interferon-free therapy being evaluated ...
Breaking Medicine Technology:Global Lab Accessories Market Report 2015-2020 - Label Printer/ Pipette tips/ Pumps/Microplate/Reagent Reservoir/Valve/Tubing/Wash Station 2Global Lab Accessories Market Report 2015-2020 - Label Printer/ Pipette tips/ Pumps/Microplate/Reagent Reservoir/Valve/Tubing/Wash Station 3Lannett Expands Revolving Credit Facility To $120 Million 2U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 2U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 3U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 4U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 5U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 6U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 7
(Date:4/25/2015)... 25, 2015 Carinsurancequotesinfo.com has released a ... low cost auto insurance for flatbed trucks. ... and sometimes other vehicles. They are mainly used for ... newly released blog post explains that by comparing multiple ... vans and other commercial vehicles. , It is now ...
(Date:4/25/2015)... Phoenix, AZ (PRWEB) April 25, 2015 Parker ... plumbing, heating, and cooling, has spiked in Arizona alongside the ... on an additional forty employees for April to help account ... , “Hiring forty employees in April is something we are ... the economy,” said Paul Kelly, president at Parker and Sons. ...
(Date:4/24/2015)... Bird B Gone, the leader in bird control products ... line of bird control solutions to address the growing threat ... Threaten Pacific, Central and Mississippi Farms , According to an ... of highly pathogenic avian flus in the Pacific, Central and ... wild birds enter poultry farms. The USDA urges farmers to ...
(Date:4/24/2015)... 2015 Carvers' goal is to ... successful biking day in Breck. , Conveniently located ... walking distance from Breckenridge, this family-owned place since ... Breckenridge bike rentals ( http://www.breckenridgeskishop.com/en/rent-equipment ) and more. ... bike rentals in May 2015. With style and ...
(Date:4/24/2015)... (PRWEB) April 24, 2015 The first ... understands the mind. , For meditation and yoga teacher ... mind have been invaluable tools that allow her to ... life. She has been a teacher since 2006, and ... her inner state of being. , “I love sharing ...
Breaking Medicine News(10 mins):Health News:Auto Insurance Quotes for Flatbed Trucks Available Online! 2Health News:Parker and Sons Plans to Expand in 2015 2Health News:Bird B Gone Offers Solutions to Bird Flu Threat to Poultry Farms 2Health News:Bird B Gone Offers Solutions to Bird Flu Threat to Poultry Farms 3Health News:Bird B Gone Offers Solutions to Bird Flu Threat to Poultry Farms 4Health News:Carvers Breckenridge Bike Rentals Offers Demo Mountain, Tandem, Bike Path Cruiser & JR. Bikes in May 2015 2
... Individual Corporate Criminal Fine in History;Civil Settlement Up To ... Lilly and Company today agreed to plead guilty and ... uses not approved by the Food and Drug Administration ... This resolution includes a criminal fine of $515 million, ...
... Peptimmune, Inc. ("Peptimmune"), a privately held ... (NYSE: NVS ) an exclusive option to ... Peptimmune,s multiple sclerosis drug candidate. In a separate but ... L.P. made an equity investment in Peptimmune.In the event ...
... Adverse prescription-drug reactions,cost the United States healthcare ... and Drug Administration, and put numerous patients at ... , In a major ... (UH) in Cleveland has launched a state-of-the-art physicians,computer ...
... 2009 Paintballs can cause severe and ,visually ... settings without proper eye protection, reports a study ... Journal of Ophthalmology (www.AJO.com), published by Elsevier. ... cause tremendous damage to vital ocular structures often ...
... 15, 2009) Tufts University has received a grant ... design an obesity prevention program for new immigrants. ... the clinical trial will randomize more than 400 ... in Somerville, Mass., and follow them for two ...
... and national governments currently debating proposals to raise alcohol ... the February edition of Addiction journal finds ... people are to drink. And when they do drink, ... four decades, researchers documented a concrete association between the ...
Cached Medicine News:Health News:Eli Lilly and Company Agrees to Pay $1.415 Billion to Resolve Allegations of Off-Label Promotion of Zyprexa 2Health News:Eli Lilly and Company Agrees to Pay $1.415 Billion to Resolve Allegations of Off-Label Promotion of Zyprexa 3Health News:Eli Lilly and Company Agrees to Pay $1.415 Billion to Resolve Allegations of Off-Label Promotion of Zyprexa 4Health News:Eli Lilly and Company Agrees to Pay $1.415 Billion to Resolve Allegations of Off-Label Promotion of Zyprexa 5Health News:Eli Lilly and Company Agrees to Pay $1.415 Billion to Resolve Allegations of Off-Label Promotion of Zyprexa 6Health News:Eli Lilly and Company Agrees to Pay $1.415 Billion to Resolve Allegations of Off-Label Promotion of Zyprexa 7Health News:Peptimmune Grants Major Pharmaceutical Company Exclusive Option to License PI-2301 for Multiple Sclerosis 2Health News:University Hospitals and OnCallData Launch New Portal Combining State-of-the- Art Electronic Prescribing and Medication Reconciliation 2Health News:University Hospitals and OnCallData Launch New Portal Combining State-of-the- Art Electronic Prescribing and Medication Reconciliation 3Health News:Paintballs can cause 'devastating' eye injuries 2Health News:Tufts receives NIH grant to study obesity prevention in new immigrants 2Health News:Tufts receives NIH grant to study obesity prevention in new immigrants 3Health News:Alcohol taxes have clear effect on drinking 2
Duckbilled spatula designed to enter a side-port stab incision with tip broad enough to efficiently manipulate the lens nucleus in the anterior chamber. Spatula is useful for rotating and cracking th...
Short handled spatula for use through the side port stab incision. The malleable silver 0.5 mm tip can be shaped to the surgeon's preference for maximum control. Round serrated handle....
... to enter a side-port stab incision ... manipulate the lens nucleus in the ... rotating and cracking the nucleus. It ... and curved shaft which facilitates nuclear ...
1 mm wide by 33 mm long malleable blade. Flat serrated handle with polished finish....
Medicine Products: